Glycemic Outcomes by Age and Previous Insulin Delivery Method in Control-IQ Technology Users: 9 Months of CLIO Study Data

Rishi Graham¹, Harsimran Singh², Lars Mueller², Kirstin White², Steph Habif², Jordan E. Pinsker² ¹University of California San Diego, San Diego, ²Tandem Diabetes Care

Background

The Control-IQ Observational (CLIO) Study is currently an ongoing IRB-approved, single-arm, longitudinal study evaluating real-world use of Tandem’s t:slim X2 insulin pump with Control-IQ technology in people with T1D (PWT1D). Previous publications from CLIO have shown glycemic improvements in ethnically diverse groups of PWT1D after 3 months of using Control-IQ technology.

Method

We evaluated relationships between glycemic metrics, participants’ age, and previous insulin delivery method at 9 months after CLIO study start. Participants (N=1913) who had uploaded at least 21 days of Control-IQ feature usage data to Tandem’s t:connect® web application (US only) and had ≥75% CGM use were included in the analysis. Impact of baseline factors on sensor glycemic outcomes were analyzed. Differences between baseline HbA1c and GMI were compared using a Wilcoxon test.

Results

Baseline HbA1c (self-reported) for the overall sample was 7.4% (median, IQR=6.8-8.3). At post with Control-IQ technology, GMI reflected significant glycemic improvement (7.06%, IQR=6.75-7.42). Previous MDI users demonstrated 71.23% TIR (61.29-81.16) and overnight TIR=75.26% (64.62-84.5) while previous pump users showed TIR=70.43% (61.27-78.67) and overnight TIR=76.39(65.46-85.12). Participants aged ≥65 years, transitioning from prior pump therapy showed the lowest GMI (median=6.87, IQR=6.62-7.17) and the highest sensor time in range (TIR) (77.94%, IQR=69.29-83.8). Younger participants although reporting higher HbA1c at baseline (6–13-year-old, 7.8% (IQR=7.1-8.6); 14–17-year-old, 8% (IQR=7.1-9)) also showed significant glycemic improvements after 9 months of using Control-IQ technology (GMI=7.4 and 7.35, respectively).

Conclusion

Long-term use of Control-IQ technology demonstrated improved glycemic metrics irrespective of participants’ age and previous insulin delivery method.

Median Glycemic Metrics

Responsible Use of Control‑IQ Technology

Even with advanced systems such as Control-IQ technology, users are still responsible for actively managing their diabetes. Control-IQ technology does not prevent all high and low blood glucose events. The system is designed to help reduce glucose variability, but it requires that users accurately input information, such as meals and periods of sleep or exercise. Control-IQ technology will not function as intended unless all system components, including CGM, infusion sets and pump cartridges, are used as instructed. Importantly, the system cannot adjust insulin dosing if the pump is not receiving CGM readings. Because there are situations and emergencies that the system may not be capable of identifying or addressing, users should always pay attention to their symptoms and treat accordingly.

References
1. Breton MD, Kovatchev BP. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021;23(9):601-608.
2. Barnard K, et al. Patient-Reported Outcomes and Continuous Glucose Monitoring: Can we do better with artificial pancreas devices? Diab Care. 2015;38(5):e70.
3. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Eng J Med. 2019;381(18):1701-1717.
4. Forlenza GP, Breton MD, Kovatchev BP. Candidate selection for Hybrid Closed Loop Systems. Diabetes Technol Ther. 2021;23(11):760-762.
5. Habif S, Singh H, et al. 217-OR: Glycemic Outcomes by Ethnicity in Adults with Type 1 Diabetes Using Control-IQ Technology: Early Results from the CLIO Study. Diabetes. 2021;70(Supplement_1):217-OR.

Important Safety Information

RX ONLY. The t:slim X2 pump and Control-IQ technology are intended for single patient use. The t:slim X2 pump and Control-IQ technology are indicated for use with U-100 insulin only.

t:slim X2 insulin pump : The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The t:slim X2 pump is indicated for use in individuals six years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons six years of age and greater.

Warning: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump and Control-IQ technology must: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. Visit www.tandemdiabetes.com/safetyinfo for additional important safety information.

Glycemic Outcomes by Age and Previous Insulin Delivery Method in Control-IQ Technology Users: 9 Months of CLIO Study Data

Background

Method

Results

Conclusion

Software

Information

Disclosures